$149 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 46 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 237.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TSHA | New | TAYSHA GENE THERAPIES INC | $12,096,246 | – | 3,827,926 | +100.0% | 8.11% | – |
| PRAX | Buy | PRAXIS PRECISION MEDICINES I | $7,669,350 | +56.9% | 4,485,000 | +5.5% | 5.14% | +55.2% |
| New | RAYZEBIO INC | $7,649,476 | – | 344,571 | +100.0% | 5.13% | – | |
| SRPT | New | SAREPTA THERAPEUTICS INCcall | $7,580,650 | – | 550 | +100.0% | 5.08% | – |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $7,417,380 | +21.9% | 362,000 | +18.2% | 4.97% | +20.6% |
| Buy | VENTYX BIOSCIENCES INC | $7,132,743 | +47.6% | 205,377 | +39.4% | 4.78% | +46.0% | |
| Buy | HILLEVAX INC | $3,635,791 | +235.3% | 270,319 | +328.5% | 2.44% | +231.6% | |
| ALKS | Buy | ALKERMES PLC | $3,543,265 | +153.3% | 126,500 | +183.1% | 2.38% | +150.5% |
| CRNX | New | CRINETICS PHARMACEUTICALS INC | $2,795,560 | – | 94,000 | +100.0% | 1.87% | – |
| REPL | New | REPLIMUNE GROUP INC | $2,566,500 | – | 150,000 | +100.0% | 1.72% | – |
| CNTA | New | CENTESSA PHARMACEUTICALS PLCsponsored ads | $2,092,068 | – | 323,349 | +100.0% | 1.40% | – |
| OLMA | Buy | OLEMA PHARMACEUTICALS INC | $1,889,636 | +97.8% | 153,007 | +44.6% | 1.27% | +95.7% |
| SRPT | New | SAREPTA THERAPEUTICS INC | $1,878,910 | – | 15,500 | +100.0% | 1.26% | – |
| REPL | New | REPLIMUNE GROUP INCcall | $1,766,000 | – | 1,000 | +100.0% | 1.18% | – |
| ETNB | New | 89BIO INCcall | $1,523,000 | – | 1,000 | +100.0% | 1.02% | – |
| DYN | Buy | DYNE THERAPEUTICS INC | $1,312,640 | +59.8% | 146,500 | +100.7% | 0.88% | +58.3% |
| KRON | Buy | KRONOS BIO INC | $934,361 | +72.5% | 718,739 | +128.2% | 0.63% | +70.6% |
| BCLI | New | BRAINSTORM CELL THERAPEUTICSput | $825,000 | – | 2,500 | +100.0% | 0.55% | – |
| IONS | New | IONIS PHARMACEUTICALS INC | $512,568 | – | 11,300 | +100.0% | 0.34% | – |
| ETNB | New | 89BIO INC | $506,432 | – | 32,800 | +100.0% | 0.34% | – |
| New | LEAP THERAPEUTICS INC | $488,749 | – | 354,166 | +100.0% | 0.33% | – | |
| New | CELLECTAR BIOSCIENCES INC. | $320,232 | – | 121,300 | +100.0% | 0.22% | – | |
| New | STRUCTURE THERAPEUTICS INCsponsored ads | $252,100 | – | 5,000 | +100.0% | 0.17% | – | |
| New | AN2 THERAPEUTICS INC | $213,864 | – | 13,300 | +100.0% | 0.14% | – | |
| New | MARINUS PHARMECEUTICALS INC | $156,975 | – | 19,500 | +100.0% | 0.10% | – | |
| MRSN | New | MERSANA THERAPEUTICS INC | $126,501 | – | 99,607 | +100.0% | 0.08% | – |
| GLYC | New | GLYCOMIMETIC INC | $41,250 | – | 27,500 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.